Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Oxford Nanopore to launch $3.4 billion London IPO in coming weeks - sources

Published 01/09/2021, 15:01
Updated 01/09/2021, 15:15
© Reuters.

© Reuters.

By Abhinav Ramnarayan

LONDON (Reuters) - Oxford Nanopore, a provider of rapid COVID-19 tests to the UK’s national health service, is working with banks to launch an initial public offering (IPO) on the London Stock Exchange in the coming weeks - a deal that would strengthen Britain's efforts to lure life science businesses to its main market.

The company aims to build on the 2.48 billion pounds ($3.42 billion) valuation achieved in a funding round in May, two sources familiar with the matter said.

The Oxford-based life sciences firm, which counts IP Group (LON:IPO) and Singapore's Temasek among its shareholders, provides DNA/RNA sequencing technology for sectors such as biomedical, pathogen, plant and animal scientific research, infectious diseases and food and agriculture. It has also worked on rapid COVID-19 tests.

The deal will add to a crowded pipeline of share sales expected to launch in London and other European centres in the last IPO window of the year as 2021 looks set for record volumes of new listings, dominated by tech and e-commerce businesses.

The Oxford Nanopore listing is a major win for London's main market as most biotech firms typically list on the LSE's junior AIM bourse before floating on Nasdaq - home to some of the world's biggest drugmakers - after reaching a certain size.

A spokesperson for the company declined to comment. Bank of America (NYSE:BAC), Citi and JPMorgan (NYSE:JPM) are global coordinators for the London listing.

In May, Oxford Nanopore held a 195 million pound funding round that saw Temasek, Wellington Management, M&G Investments and Nikon becoming new investors in the company.

Existing investors including IP Group -- which holds a 14.5% stake -- contributed 70 million pounds of the total.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.